Published in Ophthalmology on July 13, 2010
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev (2014) 1.09
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol (2013) 0.99
Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol (2011) 0.95
Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol (2013) 0.89
Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open (2015) 0.89
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol (2013) 0.88
Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol (2011) 0.86
Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol (2013) 0.84
Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol (2015) 0.84
Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. Biomed Res Int (2013) 0.84
Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol (2011) 0.84
Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol (2012) 0.81
Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. J Cell Physiol (2014) 0.80
Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol (2014) 0.79
Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion. Ophthalmol Eye Dis (2012) 0.76
Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol (2016) 0.75
Importance of Central Retinal Sensitivity for Prediction of Visual Acuity after Intravitreal Bevacizumb in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion. PLoS One (2016) 0.75
Long-term outcome after vitrectomy for macular edema with retinal vein occlusion dividing into the occlusion site. J Ophthalmol (2014) 0.75
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA (2003) 5.33
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol (2007) 3.18
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Katayama syndrome. Lancet Infect Dis (2007) 2.71
Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose. Diabetes Care (2010) 2.64
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther (2006) 2.59
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea (2002) 2.40
Evaluation of patients with scleritis for systemic disease. Ophthalmology (2004) 2.22
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol (2004) 2.12
Uveitis in patients with autoimmune hepatitis. Am J Ophthalmol (2009) 2.02
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol (2009) 1.86
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology (2005) 1.80
Recent trends in the management of rhegmatogenous retinal detachment. Surv Ophthalmol (2008) 1.78
Endothelial dystrophy, iris hypoplasia, congenital cataract, and stromal thinning (edict) syndrome maps to chromosome 15q22.1-q25.3. Am J Ophthalmol (2002) 1.56
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol (2013) 1.55
Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina (2010) 1.54
Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin Neurol Neurosurg (2008) 1.53
Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology (2007) 1.51
Progression of age-related macular degeneration after cataract surgery. Arch Ophthalmol (2009) 1.49
Risk factors predictive of severe diverticular hemorrhage. Int J Surg (2010) 1.48
Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology (2005) 1.46
Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci (2014) 1.45
Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol (2005) 1.43
New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol Scand (2007) 1.40
Blood pressure control for diabetic retinopathy. Sao Paulo Med J (2015) 1.40
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34
Effects of intracranial trochlear neurectomy on the structure of the primate superior oblique muscle. Invest Ophthalmol Vis Sci (2010) 1.32
Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag (2008) 1.27
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol (2010) 1.27
Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging (2009) 1.25
Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol (2008) 1.25
Physical activity, energy intake, sedentary behavior, and adiposity in youth. Am J Prev Med (2009) 1.24
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 1.23
Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci (2004) 1.20
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18
Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol (2010) 1.14
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13
Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology (2009) 1.12
A reduction in delayed gastric emptying by classic pancreaticoduodenectomy with an antecolic gastrojejunal anastomosis and a retrogastric omental patch. J Gastrointest Surg (2009) 1.10
Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09
Association between personal exposure to volatile organic compounds and asthma among US adult population. Int Arch Occup Environ Health (2007) 1.08
Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol (2012) 1.08
Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol (2008) 1.07
Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect (2012) 1.07
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06
Telehealth practice recommendations for diabetic retinopathy, second edition. Telemed J E Health (2011) 1.05
Telehealth practice recommendations for diabetic retinopathy. Telemed J E Health (2004) 1.04
Mental health care in the primary care setting: family physicians' perspectives. Can Fam Physician (2008) 1.04
Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East Afr J Ophthalmol (2010) 1.03
Measurement of oxygen saturation in the retina with a spectroscopic sensitive multi aperture camera. Opt Express (2008) 1.02
Vitamin D deficiency among healthy adolescents in Al Ain, United Arab Emirates. BMC Public Health (2013) 1.02
Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect (2012) 1.01
Changing patterns and outcome of Dengue infection; report from a tertiary care hospital in Pakistan. J Pak Med Assoc (2008) 1.01
Optical coherence tomography of peripheral retinal lesions in enucleated human eye specimens with histologic correlation. Am J Ophthalmol (2006) 1.01
Management of retained subretinal perfluorocarbon liquid. Ophthalmic Surg Lasers Imaging Retina (2013) 0.99
Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol (2009) 0.98
Retina-simulating phantom for optical coherence tomography. J Biomed Opt (2014) 0.97
Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm (2011) 0.96
Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. Retina (2007) 0.96
Absolute blood velocity measured with a modified fundus camera. J Biomed Opt (2010) 0.96
Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography. Invest Ophthalmol Vis Sci (2006) 0.96